Parkman Healthcare Partners LLC Takes $20.45 Million Position in IQVIA Holdings Inc. $IQV

Parkman Healthcare Partners LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 105,811 shares of the medical research company’s stock, valued at approximately $20,445,000. IQVIA accounts for approximately 2.1% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 15th biggest holding.

A number of other hedge funds have also added to or reduced their stakes in IQV. BlackRock Inc. acquired a new position in IQVIA in the second quarter valued at approximately $2,811,292,000. Boston Partners acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $676,698,000. Norges Bank bought a new stake in shares of IQVIA in the 4th quarter valued at $497,445,000. Victory Capital Management Inc. increased its stake in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of IQVIA during the 2nd quarter valued at $211,342,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

Shares of IQV stock opened at $260.30 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a fifty day simple moving average of $214.97 and a two-hundred day simple moving average of $187.62. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $261.88. The firm has a market capitalization of $42.85 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 in the last quarter. 1.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. TD Cowen increased their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. HSBC restated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. upped their price target on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.